Answers are grounded in this paper and cite their sources.
LEF1 is traditionally regarded as a crucial oncogene in colorectal cancer (CRC), and its overexpression in epithelial cells is closely linked to malignant transformation. However, whether LEF1 exerts its detrimental effects mainly within the epithelial compartment or through immunomodulatory subsets such as tumor-infiltrating regulatory T cells (Tregs) has not been systematically dissected. This retrospective study utilized nine public CRC datasets and a comprehensive bioinformatics pipeline to compare LEF1-high and LEF1-low subgroups across diverse dimensions—ranging from prognostic stratification and immune/metabolic landscapes to ligand–receptor networks and spatial compartmentalization. In parallel, LEF1 protein levels were validated by immunohistochemistry in 256 CRC specimens and correlated with clinicopathological variables. LEF1 protein and RNA levels were significantly elevated in tumor tissues compared with adjacent normal mucosa. LEF1 upregulation was associated with advanced TNM stage and poor prognosis in patients with CRC. Moreover, transcriptomic deconvolution and spatial analyses suggested an enrichment of LEF1 in submucosal Tregs, which was associated with an immunosuppressive tumor microenvironment (TME), potentially mediated by oxidative phosphorylation (OXPHOS) signatures. LEF1 overexpression in submucosal Tregs may reprogram OXPHOS, thereby contributing to an immunosuppressive TME and poor CRC prognosis; however, this axis is computationally inferred and requires future wet-lab validation.
No takes yet. Share an insight, caveat, or question.
郭泰和 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: